icon-    folder.gif   Conference Reports for NATAP  
 
  14th CROI
Conference on Retroviruses and Opportunistic Infections Los Angeles, California
Feb 25- 28, 2007
Back grey_arrow_rt.gif
 
 
 
Insulin Resistance Predicts Rapid Response in People With HCV and HIV
 
 
  Mark Mascolini
February 28, 2007
14th Conference on Retroviruses and Opportunistic Infections Los Angeles
 
Insulin resistance cut chances of a rapid virologic response (RVR) to treatment for HCV infection in people coinfected with HIV, according to results of a 56-person study at the University of Brescia in Italy.[1]. Protease inhibitor (PI) therapy, which may contribute to insulin resistance, had a smaller negative impact on chances of achieving an RVR.
 
Paola Nasta and Brescia colleagues measured insulin resistance by the HOMA-IR method in HCV/HIV-coinfected people starting 180 mcg of peglylated interferon alfa-2A weekly plus 1000 to 1200 of ribavirin daily. Everyone had received earlier anti-HCV therapy for at least 3 months.
 
Defining RVR as negative HCV-RNA by qualitative PCR 4 weeks after starting interferon/ribavirin, Nasta counted 22 people (39%) with a rapid response. Rapid responders were significantly less likely to have a HOMA-IR score above 3 (27%) than below 3 (73%) (P = 0.011) and significantly more likely to have a pretreatment HCV load below 400,000 IU/mL (59% versus 41% above 400,000 IU/mL) (P = 0.003).
 
Multivariate analysis determined that a HOMA-IR above 3 lowered the odds of RVR 86% (odds ratio [OR] 0.14, 95% confidence interval [CI] 0.03 to 0.64, P = 0.011). A pretreatment HCV reading below 400,000 IU/mL more than quadruped the chance of achieving an RVR (OR 4.63, 95% CI 1.09 to 19.6, P = 0.037). Infection with HCV genotype 1 or 4, versus genotype 2 or 3, sliced the odds of having an RVR almost 90% (OR 0.11, 95% CI 0.02 to 0.4, P = 0.003).
 
Whereas 11 of 22 people (50%) who attained an RVR were taking a PI regimen, 27 of 34 people without an RVR (79%) were taking a PI (P = 0.02). But in a multivariate analysis PI-based therapy did not independently predict failure to achieve an RVR. Still, Nasta and coworkers believe a non-PI regimen "could be an option" to increase sensitivity to anti-HCV therapy in coinfected people.
 
The Brescia researchers note that insulin resistance is a prime predictor of response to interferon/ribavirin in nondiabetic people infected with HCV but not HIV. They believe their findings support HOMA-IR as a predictor of RVR in coinfected individuals.
 
Reference
1. Nasta P, Puoti M, Gatti F, et al. HOMA-IR is a strong predictor of rapid virologic response in HIV/HCV-co-infected patients treated with pegylated interferon-alpha 2a and ribavirin. 14th Conference on Retroviruses and Opportunistic Infections. February 25-28, 2007. Los Angeles. Abstract 896.